LabCorp(R) and ARCA Discovery Partner to Commercialize Companion Diagnostic for First Cardiovascular Personalized Medicine

New test identifies genetic variants associated with patient response to new, genetically-targeted heart failure drug Agreement pioneers new model for more efficient development and application of personalized therapies BURLINGTON, N.C., and DENVER, Feb 13, 2007 /PRNewswire-FirstCall via COMTEX

LabCorp Is Scheduled To Present at the UBS Global Healthcare Services Conference

BURLINGTON, N.C., Feb. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, and Bradford T.

LabCorp Is Scheduled To Present at the Wachovia Securities 2007 Healthcare Conference

BURLINGTON, N.C., Jan. 29 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, William (Brad) Hayes, Executive Vice President and Chief Financial Officer, and Bradford T.

LabCorp Is Scheduled To Present at the 25th Annual JPMorgan Healthcare Conference

BURLINGTON, N.C., Jan. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the 25th

Conversion Right Triggered for LabCorp's Liquid Yield Option(TM) Notes Due 2021 and Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Jan 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that its zero coupon subordinated Liquid Yield Option(TM) Notes due 2021 (LYONs) and Zero Coupon Convertible Subordinated Notes due

LabCorp Is Scheduled To Present at the Merrill Lynch Health Services Investor Conference

BURLINGTON, N.C., Nov. 27 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Executive Vice President and Chief Operating Officer, Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad)

LabCorp to Dedicate New Facility at Burlington Corporate Headquarters

BURLINGTON, NC, November. 8, 2006 -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) will hold a dedication ceremony on November 16, 2006, at 10:00 a.m. for a new facility the company is constructing in Burlington, North Carolina.

LabCorp(R) Announces Accelerated Share Repurchase Agreement

Company Purchases $250 Million of Common Stock Under Accelerated Share Repurchase Agreement BURLINGTON, N.C., Nov. 6 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it has entered into an accelerated share repurchase agreement

LabCorp is Scheduled to Present at the Cowen and Company 7th Annual Global Health Care Conference

BURLINGTON, N.C., Nov. 3 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Executive Vice President and Chief Operating Officer, Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad)

Laboratory Corporation of America(R) Holdings Announces 2006 Third Quarter Results and Stock Repurchase Program

EBITDA Margin Growth Drives Operating Cash Flow of $155.0 million and EPS Increase of 22.9 Percent, Board of Directors Authorizes Additional $500 Million Share Repurchase Program BURLINGTON, N.C., Oct. 24 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: